Clinical Need for Thrombocytopenia Treatment
Thrombocytopenia can result from many factors and is a common complication of chronic liver disease. Patients with this condition have a significantly increased bleeding risk compared with healthy individuals and often require repeated platelet transfusions to manage their disease. Thrombocytopenia complicates routine care, as standard procedures such as liver biopsy or surgery can lead to exacerbated bleeding. There is a strong medical need for new treatments to address this unmet clinical need.
Mulpleta (lusutrombopag) Overview
Mulpleta (lusutrombopag), a novel drug developed by Shionogi, has been approved by the U.S. FDA for the treatment of thrombocytopenia in a specific adult patient population: patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.
This oral human thrombopoietin (TPO) receptor agonist binds to the TPO receptor on the surface of megakaryocytes, stimulating their proliferation, differentiation, and maturation, thereby increasing platelet production. Mulpleta provides a new therapeutic option for these patients.
The drug was initially approved by the Japanese Ministry of Health, Labour and Welfare in September 2015 for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure.
Clinical Efficacy of Mulpleta
The efficacy of Mulpleta was established in two randomized, double‑blind, placebo‑controlled clinical trials enrolling a total of 312 patients with chronic liver disease and thrombocytopenia (platelet count < 50 × 10⁹/L) who were scheduled for an invasive procedure. Eligible patients were randomized 1:1 to receive either 3 mg of Mulpleta or placebo.
Key Trial Results
In the first trial, 78% of patients in the Mulpleta group did not require platelet transfusion prior to the procedure, compared with only 13% in the placebo group (95% CI: 49%–79%, p<0.0001).
In the second trial, 65% of patients in the Mulpleta group avoided platelet transfusion before the procedure, versus 29% in the placebo group (95% CI: 25%–49%, p<0.0001).
Clinical Value of Mulpleta
Mulpleta not only improves thrombocytopenia in patients but also allows them to undergo standard surgical procedures without platelet transfusion, enabling timely treatment of other underlying conditions.
